10/524469
DT01 Rec'd PCT/PTO 14 FEB 2005

In the Claims:

Please amend claims 1, 3 and 5 as follows. Please add new claims 6 to 14.

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

Y is phenyl, substituted with one, two or three substituents;

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, and halosubstitutedC_{1-6} alkyl;

R^2 is $C(R^7)_2R^3$;

R^3 is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group A:



(A)

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, or halosubstitutedC_{1-6} alkyl, $COCH_3$, and SO_2Me;

R^6 is methyl, chloro or CHxFn wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;

Ra ~~can be~~ is independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

Rb ~~can be~~ is independently be selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, haloC_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, COOH or $NHCOOC_{1-6}$alkyl;

R^7 ~~can be~~ is independently hydrogen or C_{1-6} alkyl;

or a pharmaceutically acceptable derivative thereof; ~~.~~

with the proviso that the compound of Formula (I) is ~~compounds are~~ not 2-(4-*tert*-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide;
2-(4-*tert*-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzyl-methyl-amide;
2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-methoxy-benzylamide; or

2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-bromo-benzylamide.

2. (Original) A compound as claimed in claim 1 selected from any one of examples 1 to 114 or a pharmaceutically acceptable derivative thereof.

3. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~or 2 or a pharmaceutically acceptable derivative thereof~~.

4. (Original) A pharmaceutical composition as claimed in claim 3 further comprising a pharmaceutical carrier or diluent thereof.

5. (Currently Amended) A method of treating an ~~a human or~~ animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in claim 1 ~~or 2 or a pharmaceutically acceptable derivative thereof~~.

6. (New) The method as claimed in claim 5, wherein said animal is a human.

7. (New) A pharmaceutical composition comprising a compound as claimed in claim 2.

8. (New) A pharmaceutical composition as claimed in claim 7 further comprising a pharmaceutical carrier or diluent thereof.

9. (New) A method of treating an animal subject suffering from a suffering from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound as claimed in claim 1.

10. (New) The method as claimed in claim 9 wherein the pain is selected from inflammatory pain, viseral pain, cancer pain, neuropathic pain, lower back pain, muscular sceletal, post operative pain, acute pain and migraine.

11. (New) The method as claimed in claim 9, wherein said animal is a human.

12. (New) A method of treating an animal subject suffering from a suffering from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis which method comprises administering to said subject an effective amount of a compound of formula (I) as claimed in claim 2.

13. (New) The method as claimed in claim 12 wherein the pain is selected from inflammatory pain, viseral pain, cancer pain, neuropathic pain, lower back pain, muscular sceletal, post operative pain, acute pain and migraine.

14. (New) The method as claimed in claim 12, wherein said animal is a human.